Market News & Trends
Cara Therapeutics Announces Positive Topline Results From Phase 2 Trial of Oral Difelikefalin
Cara Therapeutics, Inc. recently announced positive topline results from its Phase 2 proof-of-concept clinical trial (KOMFORT) evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in….
Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Japan
Catalent recently announced it has expanded its primary packaging capabilities at its clinical supply facility in Shiga, Japan, through the installation of a high-speed blister…
BioCorRx Announces First Subject Dosed in Phase 1 Clinical Trial of Implantable Naltrexone Pellet
BioCorRx Inc. recently announced the first subject has been dosed in the Phase 1 clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the…
US Government to Support Expansion of Croda Lipid Systems Capability
Croda International Plc recently announced it has entered into a cooperative agreement with the US government in which the government will provide up to $75 million to expand the….
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy in Adults with Drug-Resistant Focal Epilepsy
Neurona Therapeutics recently announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epilepsy study…..
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
AN2 Therapeutics, Inc. recently announced it has screened its first patient in its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex…..
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor
Ventyx Biosciences, Inc. recently announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX2735, a…
SciSparc Successfully Completed Development of its Proprietary Drug Candidate for Upcoming Phase 2b Study in Tourette Syndrome
SciSparc Ltd. recently announced it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase…
Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate
Ocuphire Pharma, Inc. recently announced the USPTO has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330.…
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment
BriaCell Therapeutics Corp. recently announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty…
Norstella & Citeline Unite to Offer Life Sciences Clients a Full Suite of Commercial & Clinical Solutions
Norstella and Citeline (formerly Pharma Intelligence) have recently announced an agreement to merge the companies. By uniting Norstella, which is composed of four prominent pharmaceutical solutions providers….
Roivant and Pfizer Unveil Priovant Therapeutics & Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Roivant Sciences and Pfizer recently announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity…
Terumo Blood and Cell Technologies & GenCure Collaborate to Advance Cell & Gene Therapy Manufacturing Solutions
Terumo Blood and Cell Technologies recently announced it has signed a new collaborative agreement with GenCure, a subsidiary of BioBridge Global, to extend and unify cell and gene therapy manufacturing solutions…..
Fate Therapeutics Announces Expansion of Solid Tumor Collaboration With ONO Pharmaceutical
Fate Therapeutics, Inc. recently announced it has expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical Co., Ltd. to include the development of….
WuXi STA Opens A High-Potency API Plant
WuXi STA, a WuXi AppTec company, has recently opened another high-potency API (HPAPI) plant at its Changzhou site (Jiangsu, China). The new plant will meet…
Verrica Pharmaceuticals Holds Type A Meeting With FDA for VP-102 for Molluscum Contagiosum
Verrica Pharmaceuticals Inc. recently announced the company held a Type A meeting with the US FDA on June 27, 2022, regarding the path forward for…
Akoya Biosciences to Partner With Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature Test Into a Companion Diagnostic
Akoya Biosciences, Inc. and Acrivon Therapeutics, Inc. recently announced an agreement to co-develop, validate, and commercialize Acrivon’s OncoSignature test, a first-of-its-kind companion diagnostic. The test will…
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
Soligenix, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a Phase 2a clinical trial titled Phase 2 Study…
Vetter’s Newest Clinical Manufacturing Site Successfully Completed its First Customer Fills
With the realization of the first successful customer fills, Vetter has reached another milestone at its new clinical manufacturing facility in Rankweil, Austria. Further batches are already planned,….
Artelo Biosciences Presents Positive Pre-Clinical Results for Novel FABP5 Inhibitor
Artelo Biosciences, Inc. recently announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences, presented new research results titled Discovery and Preclinical Evaluation…
